text
"['\n4. 매출 및 수주상황\n가. 연결기준\xa0\n(단위: 백만원)\n구분\n2022년 1분기\n2021년\n2020년\n사업부문\n품목\n국내\n해외\n합계\n국내\n해외\n합계\n국내\n해외\n합계\n의약품 제조 및 판매\n혈액제제류\n80,834\n28,415\n109,249\n312,885\n132,967\n445,852\n312,061\n176,848\n488,909\nOTC류\n40,155\n255\n40,410\n174,174\n237\n174,411\n159,718\n2,211\n161,929\n일반제제류\n76,930\n18,874\n95,804\n283,655\n32,546\n316,201\n258,761\n23,815\n282,576\n백신제제\n8,524\n8,892\n17,416\n155,939\n107,229\n263,168\n253,376\n107,999\n361,375\n기타\n71,709\n16,280\n87,989\n210,773\n37,062\n247,835\n174,165\n31,484\n205,649\n검체 등 진단 및 분석\n89,062\n-\n89,062\n187,367\n-\n187,367\n99,643\n-\n99,643\n의료 서비스 및 시스템 개발공급\n35,725\n-\n35,725\n141,569\n-\n141,569\n100,577\n-\n100,577\n임대 및 서비스업\n31,727\n-\n31,727\n73,934\n-\n73,934\n78,785\n-\n78,785\n기타\n31,929\n1,426\n33,355\n151,719\n4,332\n156,051\n144,005\n6,791\n150,796\n보고부문 합계\n466,595\n74,142\n540,737\n1,692,015\n314,373\n2,006,388\n1,581,091\n349,148\n1,930,239\n연결조정 등\n-\n-\n(38,364)\n-\n-\n(165,829)\n-\n-\n(194,752)\n중단영업\n-\n-\n-\n-\n-\n-\n-\n-\n(16,161)\n연결재무제표 금액\n-\n-\n502,373\n-\n-\n1,840,559\n-\n-\n1,719,326\n\xa0\n나. 별도기준\xa0\n(단위 : 백만원)\n\xa0 \xa0 \xa0 \xa0 \xa0구 \xa0분\n2022년 1분기\n2021년\n2020년\n영업수익:\n임대료수익\n3,774\n14,712\n15,243\n배당금수익\n21,904\n32,779\n34,300\n기타영업수익\n6,049\n26,443\n29,242\n합계\n31,727\n73,934\n78,785\n다. 수주상황\n(단위 : )\n품목\n수주일자\n납기\n수주총액\n기납품액\n수주잔고\n수량\n금액\n수량\n금액\n수량\n금액\n-\n-\n-\n-\n-\n-\n-\n-\n-\n합 계\n-\n-\n-\n-\n-\n-\n']"
